The Blood Profiling Atlas in Cancer (BloodPAC) consortium published generic analytical-validation protocols for tumor‑informed circulating tumor DNA (ctDNA) assays used to monitor minimal residual disease (MRD), aiming to harmonize study designs across technology platforms. The protocols, appearing in JCO Precision Oncology, were developed by a working group spanning biotech, pharma, academia and regulators. The guidance details approaches to determine limit of detection, limit of blank, accuracy, precision, robustness, specimen stability and comparability between contrived and clinical samples. BloodPAC emphasized that the protocols are specific to MRD use cases and not directly applicable to screening, diagnosis or resistance monitoring, which require different validation strategies. BloodPAC said the standards are intended to accelerate clinical adoption of MRD tests by reducing analytical variability and providing a common, adaptable framework for assay developers and sponsors.